Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Tongue Neoplasms 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gliosarcoma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Gemcitabine 5Temozolomide 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Leucovorin 3Irinotecan 3Erlotinib Hydrochloride 3Bevacizumab 3ulixertinib 2tovorafenib 2pembrolizumab 2Trastuzumab 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Fluorodeoxyglucose F18 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Carboplatin 2vocimagene amiretrorepvec 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1spartalizumab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × FPP(RGD)2 × CNS × Clear all
NCT01806675 2019-10-03

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Stanford University

Phase 1/2 Completed
25 enrolled 14 charts
BreastCNSGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡